ESPE Abstracts (2015) 84 P-3-1175

aSection of Pediatrics, Department of Biomedical Sciences and Human Oncology, AOU Consorziale Policlinico Giovanni XXIII, Bari, Italy; bPediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy; cDepartment of Pediatrics Endocrinology, IRCCS Vita-Salute San Raffaele University, Milan, Italy; dDepartment of Pediatrics, University of Messina, Messina, Italy; eDepartment of Pediatrics, University of Foggia, Foggia, Italy


Background: Linear growth in patients with congenital hypothyroidism (CH) born in 1970s and 1980s is reported normal.

Objective and hypotheses: To evaluate whether the earlier diagnosis and the higher L-T4 starting dose lead to an improvement in growth and pubertal outcome over the last two decades.

Method: Two-hundred and fifteen patients with permanent CH born in 1980s and 1990s (age at diagnosis 25.1±10.5 days, starting treatment 8.8±2.9 (g/kg per day) were followed up until final height (FH, growth velocity <1 cm/year) was attained.

Results: Height at puberty onset −0.1±1.0 SDS, height gain during puberty −0.1±0.8 SDS. Height at puberty onset was significantly higher than target height (TH; P<0.001). The puberty onset was within the normal limits for age in 212 (98.6%) patients. FH (−0.1±1.0 SDS) was not different as compared to height at puberty onset but higher than TH (−0.8±1.0 SDS, P<0.001). FH was significantly correlated with TH (r2=0.564, P<0.001) and height at puberty onset (r2=0.685, P<0.001), but not with age at diagnosis or the starting L-T4/kg per day dose. The curve fitting analysis showed that over the two decades the age at diagnosis progressively decreased (r2=0.083, P<0.001), while the TH and the starting L-T4/kg per day progressively increased (r2=0.200, P<0.001 and r2=0.033, P=0.007 respectively). FH was not affected by the birthdate, the age at diagnosis, nor the starting L-T4 replacement dose.

Conclusion: Age at puberty onset was normal, as well as FH which was significantly higher than TH. The age at diagnosis did not play any role on FH. Despite the large improvement in the screening strategy and the treatment approach FH did not improve in patients born in 1980s and 1990s. The findings of this study are in keeping with the described secular trend in height. The early diagnosis and the treatment strategy do not seem to affect the FH.

Volume 84

54th Annual ESPE (ESPE 2015)

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.